Eintrag weiter verarbeiten
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Clinical Cancer Research, 26, 2020, 12, S. 2819-2826 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. |
|---|---|
| author |
Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. |
| spellingShingle |
Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. Clinical Cancer Research A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma Cancer Research Oncology |
| author_sort |
mita, monica m. |
| spelling |
Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-19-1430 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid tumors or lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>ASTX660 was administered orally once daily on a 7-day-on/7-day-off schedule in a 28-day cycle. Dose escalation followed a standard 3+3 design to determine the MTD and recommended phase II dose (RP2D). Dose expansion was conducted at the RP2D.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Forty-five patients received ASTX660 (range 15–270 mg/day). Dose-limiting toxicity of grade 3 increased lipase with or without increased amylase occurred in 3 patients at 270 mg/day and 1 patient at 210 mg/day. The MTD was determined to be 210 mg/day and the RP2D 180 mg/day. Common treatment-related adverse events included fatigue (33%), vomiting (31%), and nausea (27%). Grade ≥3 treatment-related adverse events occurred in 7 patients, most commonly anemia (13%), increased lipase (11%), and lymphopenia (9%). ASTX660 was rapidly absorbed, with maximum concentration achieved at approximately 0.5–1.0 hour. An approximately 2-fold accumulation in AUC exposures was observed on day 7 versus 1. ASTX660 suppressed cellular inhibitor of apoptosis protein-1 in peripheral blood mononuclear cells, which was maintained into the second cycle beyond the off-therapy week at the 180-mg/day RP2D and above. Clinical activity was seen in a patient with cutaneous T-cell lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ASTX660 demonstrated a manageable safety profile and exhibited evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D. The phase II part of the study is ongoing.</jats:p> </jats:sec> A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-19-1430 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE5LTE0MzA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE5LTE0MzA |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
American Association for Cancer Research (AACR), 2020 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2020 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
mita2020aphaseistudyofastx660anantagonistofinhibitorsofapoptosisproteinsinadultswithadvancedcancersorlymphoma |
| publishDateSort |
2020 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_unstemmed |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_full |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_fullStr |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_full_unstemmed |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_short |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_sort |
a phase i study of astx660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-19-1430 |
| publishDate |
2020 |
| physical |
2819-2826 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Purpose:</jats:title>
<jats:p>This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid tumors or lymphoma.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Patients and Methods:</jats:title>
<jats:p>ASTX660 was administered orally once daily on a 7-day-on/7-day-off schedule in a 28-day cycle. Dose escalation followed a standard 3+3 design to determine the MTD and recommended phase II dose (RP2D). Dose expansion was conducted at the RP2D.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>Forty-five patients received ASTX660 (range 15–270 mg/day). Dose-limiting toxicity of grade 3 increased lipase with or without increased amylase occurred in 3 patients at 270 mg/day and 1 patient at 210 mg/day. The MTD was determined to be 210 mg/day and the RP2D 180 mg/day. Common treatment-related adverse events included fatigue (33%), vomiting (31%), and nausea (27%). Grade ≥3 treatment-related adverse events occurred in 7 patients, most commonly anemia (13%), increased lipase (11%), and lymphopenia (9%). ASTX660 was rapidly absorbed, with maximum concentration achieved at approximately 0.5–1.0 hour. An approximately 2-fold accumulation in AUC exposures was observed on day 7 versus 1. ASTX660 suppressed cellular inhibitor of apoptosis protein-1 in peripheral blood mononuclear cells, which was maintained into the second cycle beyond the off-therapy week at the 180-mg/day RP2D and above. Clinical activity was seen in a patient with cutaneous T-cell lymphoma.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>ASTX660 demonstrated a manageable safety profile and exhibited evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D. The phase II part of the study is ongoing.</jats:p>
</jats:sec> |
| container_issue |
12 |
| container_start_page |
2819 |
| container_title |
Clinical Cancer Research |
| container_volume |
26 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348106654744577 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:05:53.871Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+Phase+I+Study+of+ASTX660%2C+an+Antagonist+of+Inhibitors+of+Apoptosis+Proteins%2C+in+Adults+with+Advanced+Cancers+or+Lymphoma&rft.date=2020-06-15&genre=article&issn=1557-3265&volume=26&issue=12&spage=2819&epage=2826&pages=2819-2826&jtitle=Clinical+Cancer+Research&atitle=A+Phase+I+Study+of+ASTX660%2C+an+Antagonist+of+Inhibitors+of+Apoptosis+Proteins%2C+in+Adults+with+Advanced+Cancers+or+Lymphoma&aulast=Tolcher&aufirst=Anthony+W.&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-19-1430&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348106654744577 |
| author | Mita, Monica M., LoRusso, Patricia M., Papadopoulos, Kyriakos P., Gordon, Michael S., Mita, Alain C., Ferraldeschi, Roberta, Keer, Harold, Oganesian, Aram, Su, Xiang Yao, Jueliger, Simone, Tolcher, Anthony W. |
| author_facet | Mita, Monica M., LoRusso, Patricia M., Papadopoulos, Kyriakos P., Gordon, Michael S., Mita, Alain C., Ferraldeschi, Roberta, Keer, Harold, Oganesian, Aram, Su, Xiang Yao, Jueliger, Simone, Tolcher, Anthony W., Mita, Monica M., LoRusso, Patricia M., Papadopoulos, Kyriakos P., Gordon, Michael S., Mita, Alain C., Ferraldeschi, Roberta, Keer, Harold, Oganesian, Aram, Su, Xiang Yao, Jueliger, Simone, Tolcher, Anthony W. |
| author_sort | mita, monica m. |
| container_issue | 12 |
| container_start_page | 2819 |
| container_title | Clinical Cancer Research |
| container_volume | 26 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid tumors or lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>ASTX660 was administered orally once daily on a 7-day-on/7-day-off schedule in a 28-day cycle. Dose escalation followed a standard 3+3 design to determine the MTD and recommended phase II dose (RP2D). Dose expansion was conducted at the RP2D.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Forty-five patients received ASTX660 (range 15–270 mg/day). Dose-limiting toxicity of grade 3 increased lipase with or without increased amylase occurred in 3 patients at 270 mg/day and 1 patient at 210 mg/day. The MTD was determined to be 210 mg/day and the RP2D 180 mg/day. Common treatment-related adverse events included fatigue (33%), vomiting (31%), and nausea (27%). Grade ≥3 treatment-related adverse events occurred in 7 patients, most commonly anemia (13%), increased lipase (11%), and lymphopenia (9%). ASTX660 was rapidly absorbed, with maximum concentration achieved at approximately 0.5–1.0 hour. An approximately 2-fold accumulation in AUC exposures was observed on day 7 versus 1. ASTX660 suppressed cellular inhibitor of apoptosis protein-1 in peripheral blood mononuclear cells, which was maintained into the second cycle beyond the off-therapy week at the 180-mg/day RP2D and above. Clinical activity was seen in a patient with cutaneous T-cell lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ASTX660 demonstrated a manageable safety profile and exhibited evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D. The phase II part of the study is ongoing.</jats:p> </jats:sec> |
| doi_str_mv | 10.1158/1078-0432.ccr-19-1430 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE5LTE0MzA |
| imprint | American Association for Cancer Research (AACR), 2020 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2020 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T18:05:53.871Z |
| match_str | mita2020aphaseistudyofastx660anantagonistofinhibitorsofapoptosisproteinsinadultswithadvancedcancersorlymphoma |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 2819-2826 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Mita, Monica M. LoRusso, Patricia M. Papadopoulos, Kyriakos P. Gordon, Michael S. Mita, Alain C. Ferraldeschi, Roberta Keer, Harold Oganesian, Aram Su, Xiang Yao Jueliger, Simone Tolcher, Anthony W. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-19-1430 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid tumors or lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>ASTX660 was administered orally once daily on a 7-day-on/7-day-off schedule in a 28-day cycle. Dose escalation followed a standard 3+3 design to determine the MTD and recommended phase II dose (RP2D). Dose expansion was conducted at the RP2D.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Forty-five patients received ASTX660 (range 15–270 mg/day). Dose-limiting toxicity of grade 3 increased lipase with or without increased amylase occurred in 3 patients at 270 mg/day and 1 patient at 210 mg/day. The MTD was determined to be 210 mg/day and the RP2D 180 mg/day. Common treatment-related adverse events included fatigue (33%), vomiting (31%), and nausea (27%). Grade ≥3 treatment-related adverse events occurred in 7 patients, most commonly anemia (13%), increased lipase (11%), and lymphopenia (9%). ASTX660 was rapidly absorbed, with maximum concentration achieved at approximately 0.5–1.0 hour. An approximately 2-fold accumulation in AUC exposures was observed on day 7 versus 1. ASTX660 suppressed cellular inhibitor of apoptosis protein-1 in peripheral blood mononuclear cells, which was maintained into the second cycle beyond the off-therapy week at the 180-mg/day RP2D and above. Clinical activity was seen in a patient with cutaneous T-cell lymphoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ASTX660 demonstrated a manageable safety profile and exhibited evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D. The phase II part of the study is ongoing.</jats:p> </jats:sec> A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma Clinical Cancer Research |
| spellingShingle | Mita, Monica M., LoRusso, Patricia M., Papadopoulos, Kyriakos P., Gordon, Michael S., Mita, Alain C., Ferraldeschi, Roberta, Keer, Harold, Oganesian, Aram, Su, Xiang Yao, Jueliger, Simone, Tolcher, Anthony W., Clinical Cancer Research, A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma, Cancer Research, Oncology |
| title | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_full | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_fullStr | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_full_unstemmed | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_short | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| title_sort | a phase i study of astx660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma |
| title_unstemmed | A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-19-1430 |